Transient Hypothyroidism after Iodine-131 Therapy for Grave’s Disease

Núria Gómez, José M. Gómez, Amat Orti, Laura Gavaldà, Carles Villabona, Pere Leyes and Joan Soler

Department of Endocrinology, Ciutat Sanitària and University of Bellvitge, Barcelona, Spain

We studied 355 patients with Grave's disease to characterize transient hypothyroidism and its prognostic value following 131I therapy. Methods: The patients received therapeutic 131I treatment as follows: 333 received a dose <10 mCi (6.6 ± 1.9 mCi) and 22 received a dose >10 mCi (12.8 ± 2.9 mCi). Diagnosis of transient hypothyroidism was based on low T4, regardless of TSH within the first year after 131I followed by recovery of T4 and normal TSH. Results: After administration of <10 mCi 131I, 40 patients developed transient hypothyroidism during the first year; transient hypothyroidism was symptomatic in 15. There was no transient hypothyroidism after high doses (>10 mCi) of 131I. Iodine-131 uptake >70% at 2 hr before treatment was a risk factor for developing transient hypothyroidism (Odds ratio 2.8, 95% confidence interval 0.9–9.4). At diagnosis of transient hypothyroidism, basal TSH levels were high (51%), normal (36%); or low (14%); therefore, the transient hypothyroidism was not centralised. If hypothyroidism developed during the first 6 mo after basal TSH >45 mU/liter ruled out transient hypothyroidism. Conclusion: The development of transient hypothyroidism and its hormonal pattern did not influence long-term thyroid function. Since no prognostic factors reliably predicted transient hypothyroidism before 131I or at the time of diagnosis, if hypothyroidism appears within the first months after 131I, the reevaluation of thyroid function later is warranted to avoid unnecessary chronic replacement therapy.

Key Words: Grave's disease; iodine-131 therapy; transient hypothyroidism; permanent hypothyroidism


Since antithyroid drugs are often ineffective in inducing long-term remission of Grave’s disease, most patients with Grave’s disease require definitive therapy with 131I or subtotal thyroidectomy. Iodine-131 is increasingly becoming the treatment of choice since it is effective and safe, but hypothyroidism is an unavoidable consequence which increases with time after treatment, especially after high dose therapy (1–3). Some patients, however, develop transient hypothyroidism within the first months after 131I therapy (4). Although the diagnostic value of transient hypothyroidism is to avoid unnecessary chronic replacement ther-

apy, its incidence and characteristics are not well known (5). Recurrent as well as late permanent hypothyroidism have been described in patients with previous transient hypothyroidism (6), but no effective means to predict it are well known.

We undertook this study to: (a) characterize transient hypothyroidism after 131I therapy for Grave’s disease, (b) seek predictive factors of transient hypothyroidism before 131I therapy, (c) differentiate transient hypothyroidism from permanent hypothyroidism at the time of diagnosis and (d) assess the predictive value of transient hypothyroidism in long-term thyroid function.

MATERIALS AND METHODS

Patients

From 1979 to 1991, 372 patients underwent therapeutic 131I treatment for Grave's disease. Due to insufficient data from follow-up, 17 patients were excluded from the analysis. Thus, we report on 355 patients.

Diagnosis of Grave's disease was based on clinical features, subnormal serum concentration of thyrotropin (TSH) with concomitant increase in thyroxine (T4) or triiodothyronine levels (T3) or both. Diffuse goiter was assessed scintigraphically.

The patients (333) were treated with calculated low doses of 131I lower than 10 mCi (6.6 ± 1.9 mCi) determined by gland weight and 131I uptake at 2 and 24 hr. The remaining 22 patients were treated with a dose higher than 10 mCi (12.8 ± 2.9 mCi) because of severe associated illness and/or persistent hyperthyroidism after low dose administration.

Two hundred and seven patients (58%) were treated with antithyroid drugs for a minimum of 6 mo and 13 patients underwent subtotal thyroidectomy as the first therapeutic option before 131I treatment. No patient received antithyroid drugs after 131I therapy.

Follow-up

Clinical examination and T4, T3 and basal TSH measurements were performed at monthly intervals during the first 6 mo, at 12 mo and then yearly until permanent hypothyroidism developed. The mean follow-up period was 34.3 mo (range 12–145).

Within the first 6 mo after 131I therapy, hypothyroidism was diagnosed by low T4 levels regardless of TSH levels, with or without hypothyroid symptoms. If T4 levels later became normal and the basal TSH levels were lower than 8 mU/liter, the diagnosis transient hypothyroidism, but when TSH levels were higher than 8 mU/liter, the diagnosis was permanent hypothyroidism (7).

In the first 6 mo, transient thyroxine replacement was started in asymptomatic patients and withdrawn before the next therapeutic

Received May 3, 1994; revision accepted May 15, 1995.

For correspondence or reprints contact: Núria Gómez Amalz, MD, C/ Congost 30-32 4ª, Barcelona 08024, Spain.
course. Patients whose hyperthyroidism relapsed were treated with an additional 131I dose.

**Measurements**

Total serum T4 (normal values 70–170 nmole/liter), T3 (normal values 1.2–3 nmole/liter) and TSH (normal values 0.1–4 mU/liter) were measured by specific radioimmunoassays. From 1986, hormone levels were determined by enzymoimmunoassays. Thyroid uptake of 131I at 2 and 24 hr was calculated from a 50-mCi tracer dose given before the therapeutic dose.

**Data Analysis**

We analyzed the following variables: sex, age, previous antithyroid drug intake and surgical treatment, 131I uptake at 2 and 24 hr, T4 and T3 levels before 131I therapy, 131I to dose-induced transient hypothyroidism, the 131I accumulative dose (in mCi) and T4, T3 and basal TSH levels during transient hypothyroidism. Data were expressed as mean ± s.d. Variables were compared by chi square testing and analysis of variance (SPSS program) (8).

Survival analysis of disease by the Kaplan-Meier method (9) was performed and time-dependent variables analyzed by the Mantel-Cox method (BMDP11 program) to describe the time course of thyroid function after 131I therapy (10, 11). Patients who developed permanent hypothyroidism during the first 6 mo after 131I therapy were excluded from life-table analysis because it is not possible that transient hypothyroidism developed during the same period. To predict risk factors for developing transient hypothyroidism, patients were distributed into categories of exposure for each variable, and the Odds ratio was estimated with a multivariate statistic model by conditional logistic regression using the likelihood ratio method (EGRET program).

**RESULTS**

Of the 333 patients treated with calculated low doses of 131I, transient hypothyroidism was diagnosed in 40 (29 women, 11 men, aged 28–71 yr; mean, 48.8 yr). Twenty-six patients developed transient hypothyroidism after the first dose of 131I, nine after the second and two after the third. Three patients developed transient hypothyroidism twice (two patients after the first and second 131I doses and a third after the second and fourth 131I doses), making the total number of transient hypothyroidism episodes 43. Transient hypothyroidism was not diagnosed after high dose therapy. No differences were observed in clinical and laboratory findings at the time of 131I therapy or in thyroid function after 131I administration between patients treated with low and high doses (data not shown).

 Patients with and without transient hypothyroidism were compared to predict the development of transient hypothyroidism (Table 1). Pretreatment T4 and T3 levels and 131I uptake at 2 hr postadministration were higher in the transient hypothyroidism group. After multivariate statistical analysis, only 131I uptake higher than 70% at 2 hr was a significant risk factor for developing transient hypothyroidism (Odds ratio 2.8, confidence interval 0.9–9.4), with a positive predictive value of 28.1% and a negative predictive value of 89.7%.

The time of diagnosis of transient hypothyroidism was 2.1 ± 1 mo after 131I (range 1–6 mo). Recovery of thyroid function was delayed 3 ± 1.1 mo (range 1–5 mo).

*All values are expressed as mean ± s.d. for continuous variables and as the percentage (number in parentheses) for categorical variables.

The hormonal pattern at the time of transient hypothyroidism diagnosis was: low T4 in all 40 patients, low T3 in 29, high basal TSH in 22, normal TSH in 15 and low TSH in 6 (<0.1 mU/liter) (Fig. 1). No variable correlated with the hormonal pattern or transient hypothyroidism duration (data not shown).

Hypothyroid symptoms were present in 15 patients (37.5%) and thyroxine replacement was started (mean duration, 2.4 mo; range, 1–4 mo).

To differentiate transient hypothyroidism from permanent hypothyroidism, patients who developed permanent hypothyroidism during the first 6 mo after 131I were compared with transient hypothyroidism patients (Table 2). No patient with basal TSH higher than 45 mU/liter had transient hypothyroidism. Therefore, TSH levels higher than 45 mU/liter had a 100% positive predictive value for permanent hypothyroidism in the first months after 131I treatment.

At the 12th mo, 34 patients with transient hypothyroidism were euthyroid and only two of these had TSH levels

### Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>TH</th>
<th>No TH</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>40</td>
<td>293</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11 (27.5%)</td>
<td>77 (26.3%)</td>
<td>ns</td>
</tr>
<tr>
<td>Female</td>
<td>29 (72.5%)</td>
<td>216 (73.7%)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>49 ± 12</td>
<td>51 ± 11</td>
<td>ns</td>
</tr>
<tr>
<td>Previous antithyroid drug treatment</td>
<td>16 (40%)</td>
<td>123 (41.9%)</td>
<td>ns</td>
</tr>
<tr>
<td>Previous surgery</td>
<td>0</td>
<td>13 (4.4%)</td>
<td>ns</td>
</tr>
<tr>
<td>T4 (nmole/liter)</td>
<td>277 ± 67</td>
<td>245 ± 60</td>
<td>0.001</td>
</tr>
<tr>
<td>T3 (nmole/liter)</td>
<td>6.4 ± 1.9</td>
<td>5.4 ± 2.2</td>
<td>0.004</td>
</tr>
<tr>
<td>131I uptake at 2 hr (%)</td>
<td>53 ± 21</td>
<td>44 ± 20</td>
<td>0.009</td>
</tr>
<tr>
<td>131I uptake at 24 hr (%)</td>
<td>54 ± 17</td>
<td>60 ± 17</td>
<td>ns</td>
</tr>
<tr>
<td>Initial dose (mCi)</td>
<td>6.9 ± 1.9</td>
<td>6.5 ± 1.9</td>
<td>ns</td>
</tr>
<tr>
<td>Total dose (mCi)</td>
<td>10.6 ± 6.3</td>
<td>8.4 ± 4.6</td>
<td>0.008</td>
</tr>
</tbody>
</table>

*All variables are expressed as mean ± s.d. for continuous variables and as the percentage (number in parentheses) for categorical variables.
TABLE 2
Clinical and Laboratory Findings

<table>
<thead>
<tr>
<th>Variable</th>
<th>TH</th>
<th>PH</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>40</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11 (27.5%)</td>
<td>31 (28.2%)</td>
<td>ns</td>
</tr>
<tr>
<td>Female</td>
<td>29 (72.5%)</td>
<td>79 (71.8%)</td>
<td>ns</td>
</tr>
<tr>
<td>Age</td>
<td>49 ± 12</td>
<td>50 ± 11</td>
<td>ns</td>
</tr>
<tr>
<td>Previous antithyroid drug treatment</td>
<td>16 (40%)</td>
<td>55 (50%)</td>
<td>ns</td>
</tr>
<tr>
<td>Previous surgery</td>
<td>0</td>
<td>3 (2.7%)</td>
<td>ns</td>
</tr>
<tr>
<td>Pretreatment T4 (nmol/liter)</td>
<td>277 ± 67</td>
<td>245 ± 57</td>
<td>0.003</td>
</tr>
<tr>
<td>Pretreatment T3 (nmol/liter)</td>
<td>6.4 ± 1.9</td>
<td>5.3 ± 2.1</td>
<td>0.003</td>
</tr>
<tr>
<td>131I uptake at 2 hr (%)</td>
<td>53 ± 21</td>
<td>42 ± 19</td>
<td>0.003</td>
</tr>
<tr>
<td>131I uptake at 24 hr (%)</td>
<td>54 ± 17</td>
<td>59 ± 17</td>
<td>ns</td>
</tr>
<tr>
<td>Initial dose (mCi)</td>
<td>6.9 ± 1.9</td>
<td>6.3 ± 1.9</td>
<td>ns</td>
</tr>
<tr>
<td>Total dose (mCi)</td>
<td>10.6 ± 6.3</td>
<td>7.9 ± 4.1</td>
<td>0.002</td>
</tr>
<tr>
<td>T4 at diagnosis of hypothyroidism</td>
<td>41 ± 18</td>
<td>36 ± 23</td>
<td>ns</td>
</tr>
<tr>
<td>T3 at diagnosis of hypothyroidism</td>
<td>1.1 ± 0.4</td>
<td>1.1 ± 0.6</td>
<td>ns</td>
</tr>
<tr>
<td>Basal TSH at diagnosis of hypothyroidism (mU/liter)</td>
<td>13.3 ± 10.6</td>
<td>44.9 ± 33.9</td>
<td>0.001</td>
</tr>
</tbody>
</table>

*According to development of transient (TH) or permanent (PH) hypothyroidism in the first 6 mo after 131I Therapy

*All values are expressed as mean ± s.d. for continuous variables and as the percentage (numbers in parentheses) for categorical variables.

between 4 and 8 mU/liter which had normalized in the next treatment course with no thyroxine replacement. In the remaining six patients, hyperthyroidism relapsed during the first 6 mo after transient hypothyroidism diagnosis. No differences were observed during 131I therapy or transient hypothyroidism between patients who relapsed and those who became euthyroid after diagnosis of transient hypothyroidism (data not shown).

Life-table analysis showed an 81.4% risk of permanent hypothyroidism 141 mo after 131I therapy for patients who previously developed transient hypothyroidism versus 89.9% for patients without transient hypothyroidism (p = 0.64) (Fig. 2). TSH levels at the onset and end of transient hypothyroidism did not correlate with the probability of late-onset permanent hypothyroidism (p = 0.53).

DISCUSSION

The incidence of transient hypothyroidism in patients treated with low-dose radioiodine was 12.1% and has been reported to range from 3.8% to 28% (5,6,12–16). These variations may result not only from differences in follow-up and the administered 131I dose but also from the imprecise definition of transient hypothyroidism in many reports. Our series included patients diagnosed with transient hypothyroidism if T4 levels were low, regardless of basal TSH in the first months after 131I therapy, followed by T4 level normalization and serum TSH levels lower than 8 mU/liter during the next few months. TSH levels at the time of the transient hypothyroidism diagnosis were excluded from diagnostic criteria because of the slow recovery of TSH secretion after long-term suppression in thyrotoxic patients (4,17–20). We found that transient hypothyroidism developed within the first 6 mo and disappeared within the first year after 131I therapy. Patients with basal TSH levels between 4 and 8 mU/liter after recovery of peripheral thyroid function were included in the analysis since these levels normalized spontaneously. In contrast, patients with high basal TSH levels who were treated with 131I should be considered as having permanent hypothyroidism (4–6,14,16,19).

Transient hypothyroidism did not develop in those patients with Grave’s disease who received 131I doses greater than 10 mCi. This factor may be related to the small number of patients included in this group (n = 22); however, transient hypothyroidism has not been described in patients who received high doses of 131I (1–3).

After multivariate statistical analysis, the only significant risk factor for developing transient hypothyroidism was 131I uptake at 2 hr higher than 70% before therapy. This should be considered a negative risk factor because of the low positive predictive value (28.1%) and high negative predictive value (89.7%).

The main problem in clinical practice is to differentiate transient hypothyroidism from permanent hypothyroidism in the early months after therapy. We found that TSH levels higher than 45 mU/liter were a predictive factor for permanent hypothyroidism, with a specificity of 100%.

According to some authors, transient hypothyroidism is a central hypothyroidism phase during recovery of the hypothalamic-pituitary axis after 131I treatment (21). Our results do not support this hypothesis since basal TSH levels were high (51%), normal (35%) or low (14%) at the onset of transient hypothyroidism and the time of recovery of thyroid function did not correlate with initial TSH levels.
Moreover, transient hypothyroidism is not present in other hyperthyroid etiologies with proven pituitary suppression after therapy (22). In contrast, other authors suggest that previous treatment with antithyroid drugs may induce intrathyroidal iodine depletion and, after $^{131}$I therapy, a reduction in the entrapment of iodine by the gland may impair the maintenance of thyroid hormone production (23). In our study, antithyroid pretreatment was not associated with development of transient hypothyroidism. Finally, transient hypothyroidism may be immunemediated by TSH receptor antibodies, which may account for the specificity of transient hypothyroidism in Grave’s disease. Thus, $^{131}$I therapy would cause diffuse thyroid damage and a simultaneous rise in thyrotropin receptor antibodies (24–27), which may be blockers. This analysis was not possible in our series because many of the patients did not have these antibodies. The outcome for patients with transient hypothyroidism is not well known (5,6,16). Recurrent hypothyroidism has been described (6,16) and was also diagnosed in six of our patients. Analysis by the Mantel-Cox method showed that residual thyroid function did not differ from that of patients without previous transient hypothyroidism and was independent of TSH levels during transient hypothyroidism.

CONCLUSION

Transient hypothyroidism developed in 12.1% of patients treated with low-dose $^{131}$I for Grave’s disease during the first year after $^{131}$I therapy and was asymptomatic in most patients. Transient hypothyroidism did not develop after administration of doses higher than 10 mCi. Transient hypothyroidism was not a central hypothyroidism since TSH levels were high, normal or low at transient hypothyroidism onset and did not correlate with the time of recovery. There was no prognostic factor to reliably predict transient hypothyroidism before $^{131}$I therapy or at the time of diagnosis. TSH levels higher than 45 mU/liter ruled out transient hypothyroidism. In view of our findings, the possibility of spontaneous recovery of thyroid function should be considered before making a diagnosis of definitive hypothyroidism within the first months after $^{131}$I therapy, particularly if TSH levels are lower than 45 mU/liter. Consequently, we recommend later assessment of thyroid function, for example, 6 mo after $^{131}$I therapy, because at that time all of our patients with transient hypothyroidism had recovered their thyroid function. Although transient hypothyroidism was not a prognostic index future thyroid function, its clinical significance lies in accurate diagnosis to avoid chronic thyroxine replacement.

ACKNOWLEDGMENT

The authors thank Mrs. Cristine O’Hara for her editorial services.

REFERENCES